clinical trial · NCT00410761
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Genzyme, a Sanofi Company·phase3·completed·n = 331
Thyroid CancerZD6474 (Vandetanib)
brief summary
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
started
Nov 23, 2006
primary completion
Jul 31, 2009
completion
Jul 26, 2024
last updated
Sep 24, 2025
official title
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol